Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 931

1.

Determinants of direct cost differences among US employees with major depressive disorders using antidepressants.

Birnbaum HG, Ben-Hamadi R, Greenberg PE, Hsieh M, Tang J, Reygrobellet C.

Pharmacoeconomics. 2009;27(6):507-17. doi: 10.2165/00019053-200927060-00006.

PMID:
19640013
[PubMed - indexed for MEDLINE]
2.

Pharmacy and medical costs associated with switching between venlafaxine and SSRI antidepressant therapy for the treatment of major depressive disorder.

Khandker RK, Kruzikas DT, McLaughlin TP.

J Manag Care Pharm. 2008 Jun;14(5):426-41.

PMID:
18597572
[PubMed - indexed for MEDLINE]
Free Article
3.

Costs associated with changes in antidepressant treatment in a managed care population with major depressive disorder.

Schultz J, Joish V.

Psychiatr Serv. 2009 Dec;60(12):1604-11. doi: 10.1176/appi.ps.60.12.1604.

PMID:
19952150
[PubMed - indexed for MEDLINE]
4.

Antidepressant treatment patterns and costs among US employees.

Birnbaum H, Greenberg PE, Tang J, Hsieh M, Wu EQ, Amand C, Ben-Hamadi R.

J Med Econ. 2009 Mar;12(1):36-45. doi: 10.3111/13696990902757389.

PMID:
19450063
[PubMed - indexed for MEDLINE]
5.

Economic implications of treatment-resistant depression among employees.

Greenberg P, Corey-Lisle PK, Birnbaum H, Marynchenko M, Claxton A.

Pharmacoeconomics. 2004;22(6):363-73.

PMID:
15099122
[PubMed - indexed for MEDLINE]
6.

Differences in medication adherence and healthcare resource utilization patterns: older versus newer antidepressant agents in patients with depression and/or anxiety disorders.

Sheehan DV, Keene MS, Eaddy M, Krulewicz S, Kraus JE, Carpenter DJ.

CNS Drugs. 2008;22(11):963-73.

PMID:
18840035
[PubMed - indexed for MEDLINE]
7.

The direct costs of untreated comorbid insomnia in a managed care population with major depressive disorder.

Asche CV, Joish VN, Camacho F, Drake CL.

Curr Med Res Opin. 2010 Aug;26(8):1843-53. doi: 10.1185/03007995.2010.488037.

PMID:
20515321
[PubMed - indexed for MEDLINE]
8.

The impact of treatment-resistant depression on health care utilization and costs.

Crown WH, Finkelstein S, Berndt ER, Ling D, Poret AW, Rush AJ, Russell JM.

J Clin Psychiatry. 2002 Nov;63(11):963-71.

PMID:
12444808
[PubMed - indexed for MEDLINE]
9.
10.

Overlap of anxiety and depression in a managed care population: Prevalence and association with resource utilization.

McLaughlin TP, Khandker RK, Kruzikas DT, Tummala R.

J Clin Psychiatry. 2006 Aug;67(8):1187-93.

PMID:
16965195
[PubMed - indexed for MEDLINE]
11.

Escitalopram and duloxetine in major depressive disorder: a pharmacoeconomic comparison using UK cost data.

Wade AG, Fern├índez JL, Fran├žois C, Hansen K, Danchenko N, Despiegel N.

Pharmacoeconomics. 2008;26(11):969-81.

PMID:
18850765
[PubMed - indexed for MEDLINE]
12.

Major depressive disorder, somatic pain, and health care costs in an urban primary care practice.

Gameroff MJ, Olfson M.

J Clin Psychiatry. 2006 Aug;67(8):1232-9.

PMID:
16965201
[PubMed - indexed for MEDLINE]
13.

Identification of a claims data "signature" and economic consequences for treatment-resistant depression.

Corey-Lisle PK, Birnbaum HG, Greenberg PE, Marynchenko MB, Claxton AJ.

J Clin Psychiatry. 2002 Aug;63(8):717-26.

PMID:
12197453
[PubMed - indexed for MEDLINE]
14.

The cost of comorbid depression and pain for individuals diagnosed with generalized anxiety disorder.

Zhu B, Zhao Z, Ye W, Marciniak MD, Swindle R.

J Nerv Ment Dis. 2009 Feb;197(2):136-9. doi: 10.1097/NMD.0b013e3181963486.

PMID:
19214050
[PubMed - indexed for MEDLINE]
15.

Cost of post-traumatic stress disorder vs major depressive disorder among patients covered by medicaid or private insurance.

Ivanova JI, Birnbaum HG, Chen L, Duhig AM, Dayoub EJ, Kantor ES, Schiller MB, Phillips GA.

Am J Manag Care. 2011 Aug 1;17(8):e314-23.

PMID:
21851139
[PubMed - indexed for MEDLINE]
Free Article
16.

Interstitial Cystitis: Cost, treatment and co-morbidities in an employed population.

Wu EQ, Birnbaum H, Mareva M, Parece A, Huang Z, Mallett D, Taitel H.

Pharmacoeconomics. 2006;24(1):55-65.

PMID:
16445303
[PubMed - indexed for MEDLINE]
17.

Differences in total medical costs across the SSRIs for the treatment of depression and anxiety.

Sheehan DV, Eaddy MT, Shah MB, Mauch RP.

Am J Manag Care. 2005 Oct;11(12 Suppl):S354-61.

PMID:
16236017
[PubMed - indexed for MEDLINE]
Free Article
18.

Economic impact of therapeutic substitution of a brand selective serotonin reuptake inhibitor with an alternative generic selective serotonin reuptake inhibitor in patients with major depressive disorder.

Wu EQ, Yu AP, Lauzon V, Ramakrishnan K, Marynchenko M, Ben-Hamadi R, Blum S, Erder MH.

Ann Pharmacother. 2011 Apr;45(4):441-51. doi: 10.1345/aph.1P482. Epub 2011 Mar 17.

PMID:
21415162
[PubMed - indexed for MEDLINE]
19.

The cost of disability and medically related absenteeism among employees with multiple sclerosis in the US.

Ivanova JI, Birnbaum HG, Samuels S, Davis M, Phillips AL, Meletiche D.

Pharmacoeconomics. 2009;27(8):681-91. doi: 10.2165/11314700-000000000-00000.

PMID:
19712010
[PubMed - indexed for MEDLINE]
20.

Economic burden of epilepsy among the privately insured in the US.

Ivanova JI, Birnbaum HG, Kidolezi Y, Qiu Y, Mallett D, Caleo S.

Pharmacoeconomics. 2010;28(8):675-85. doi: 10.2165/11535570-000000000-00000.

PMID:
20623993
[PubMed - indexed for MEDLINE]

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk